Related Experiment Video
Updated: Aug 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening
Y H Zhang1, L L McCabe, M Wilborn
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030.
Insights
Molecular genetic testing in newborn screening for hemoglobinopathies, like sickle cell anemia, significantly speeds up diagnosis. This allows for earlier penicillin prophylaxis, reducing infant morbidity and mortality.
Area of Science:
- Medical Genetics
- Molecular Biology
- Neonatal Screening
Background:
- Newborn screening for hemoglobinopathies reduces infant morbidity and mortality.
- Early penicillin prophylaxis by 4 months is crucial for managing sickle cell anemia.
- Timely diagnostic confirmation is essential for effective newborn screening programs.
Purpose of the Study:
- To assess the feasibility of integrating molecular genetic follow-up testing into neonatal hemoglobinopathy screening.
- To determine if molecular genetic testing reduces the time to diagnostic confirmation.
Main Methods:
- Compared allele-specific cleavage (ASC) with allele-specific oligonucleotide (ASO) hybridization for molecular genetic analysis.
- Utilized dried blood specimens from the Texas Neonatal Hemoglobinopathy Screening Program.
- Developed an automated microtiter plate-based method for ASC analysis.
Main Results:
- Molecular genetic analyses were definitive for 506 out of 518 specimens.
- ASC and ASO hybridization showed agreement in all analyzed specimens.
- Rapid molecular genetic analysis reduced the mean age at confirmation by approximately 50% to 2 months.
- Identified approximately 13% of screened FS individuals as probable S/beta-thalassemia.
Conclusions:
- Allele-specific cleavage (ASC) is a reliable method for molecular genetic analysis of dried blood specimens.
- Automated ASC methods can reduce labor, costs, and increase throughput.
- Molecular genetic analysis of newborn screening specimens significantly reduces diagnostic confirmation time, ensuring prophylaxis before 4 months of age.
Abstract:
Newborn screening for the hemoglobinopathies has been shown to reduce morbidity and mortality, particularly for sickle cell anemia, by facilitating initiation of penicillin prophylaxis by 4 months of age. The purpose of the current investigation was to determine whether molecular genetic follow-up testing could be introduced into a neonatal hemoglobinopathy screening program and, if successfully introduced, whether it would reduce time to diagnostic confirmation. Between July 1, 1991, and October 7, 1992, 518 original dried blood specimens were referred from the Texas Department of Health Neonatal Hemoglobinopathy Screening Program for molecular genetic follow-up testing. Allele-specific cleavage (ASC) after amplification with matched and mismatched polymerase chain reaction primers was compared to allele-specific oligonucleotide (ASO) hybridization. By November 2, 1992, molecular genetic analyses were definitive in 506, and agreement was observed between ASC and ASO hybridization in all specimens analyzed. Approximately 13% of those initially screened FS were considered probable S/beta-thal by DNA and RNA testing. Rapid molecular genetic analysis contributed to a substantial reduction of the mean age at confirmation by approximately 50%, to about 2 months of age. ASC is a reliable method for molecular genetic analysis of dried blood specimens, providing methodology which can be readily automated. An automated method is demonstrated that is based on microtiter plate technology and will significantly reduce labor intensity and costs, while increasing sample throughput. Even with current manual testing methods, DNA and RNA analysis of initial newborn screening specimens will reduce the age at confirmation well under 4 months, the age cut-off for effective initiation of penicillin prophylaxis.
More Related Videos
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets

